Mitchell L. Ramsey

Mitchell L. Ramsey

Auto-generated profile, based on publicly available information

Mitchell L. Ramsey

The Ohio State University Wexner Medical Center, Ohio, United States

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Pancreatology
Verified
Journal Article
Closed access
MRMitchell L. Ramsey
Mitchell L. Ramsey
ETErin Talbert
Erin Talbert
DADaniel Ahn
Daniel Ahn
TBTanios Bekaii-Saab
Tanios Bekaii-Saab
NBNiharika Badi
Niharika Badi
PHPhil A. Hart
Phil A. Hart

14 August 2019 in Trials
Verified
Journal Article
Open access
PDF file
OTon behalf of the TACTIC Investigative Team
on behalf of the TACTIC Investigative Team
MRMitchell L. Ramsey
Mitchell L. Ramsey
JNJanet Nuttall
Janet Nuttall
PHPhil A. Hart
Phil A. Hart
Chronic pancreatitis (CP) is a progressive, fibro-inflammatory disease characterized by enzymatic autoactivation and subsequent fibrotic replacement of acinar cells. A significant proportion of patients develop pain, which may be due to many causes, including perineural inflammation, altered central processing of pain signals, parenchymal structural changes, and ductal obstruction. Currently there are no approved medical treatment options for CP-associated pain. NI-03 (camostat mesilate) is an orally administered serine protease inhibitor that reduces pancreatic enzyme activity and has been widely used for the treatment of CP-associated pain in Japan. The current study will assess the safety and efficacy of NI-03 for reduction of CP-associated pain in the USA. The current study consists of two phases. First, a phase I study will be performed to establish the pharmacokinetics and safety profile over a 1-week period following a single dose (100, 200, or 300 mg). Subsequently, a phase II study will be performed consisting of a double-blind, randomized, controlled trial (RCT). This RCT will evaluate the efficacy of each of the three doses of NI-03 given three times daily compared to placebo over 28 days. A 7-day, single-blind, run-in period will precede the double-blind phase to assess baseline pain characteristics. The primary efficacy outcome is the average of worst daily pain scores (numeric rating scale of 0–10) over the terminal 7 days of the study period compared to baseline. Secondary efficacy outcomes include change in opioid dose and quality of life measures, and time to first rescue intravenous analgesic. Adverse events will be recorded. NI-03 has been used successfully and safely in Japan to treat CP-associated pain. The aim of the current study is to assess the safety and efficacy of NI-03 using a rigorous RCT in a population in the USA. This study may fill an important clinical gap to provide an effective medical treatment option for CP-associated pain. ClinicalTrials.gov, NCT02693093 . Registered through the National Institutes of Health on 26 February 2016.

23 August 2022 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
MRMitchell L. Ramsey
Mitchell L. Ramsey
SLSusan S. Li
Susan S. Li
LLLuis F. Lara
Luis F. Lara
YGYevgeniya Gokun
Yevgeniya Gokun
VAVenkata Akshintala
Venkata Akshintala
PHPhil A. Hart
Phil A. Hart

17 June 2022 in Familial Cancer
Verified
Journal Article
Closed access
PDF file
MRMitchell L. Ramsey
Mitchell L. Ramsey
JTJewel Tomlinson
Jewel Tomlinson
RPRachel Pearlman
Rachel Pearlman
LALaith Abushahin
Laith Abushahin
AAAmber Aeilts
Amber Aeilts
HHHeather Hampel
Heather Hampel

19 October 2021 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
MRMitchell L. Ramsey
Mitchell L. Ramsey
YGYevgeniya Gokun
Yevgeniya Gokun
LSLindsay A. Sobotka
Lindsay A. Sobotka
MWMichael R. Wellner
Michael R. Wellner
KPKyle Porter
Kyle Porter
LLLuis F. Lara
Luis F. Lara
INTRODUCTION: Acute pancreatitis (AP) occurs among patients with pancreas-sufficient cystic fibrosis (PS-CF) but is reportedly less common among patients with pancreas-insufficient cystic fibrosis (PI-CF). The incidence of AP may be influenced by cystic fibrosis transmembrane conductance regulator (CFTR) modulator use. We hypothesized that CFTR modulators would reduce AP hospitalizations, with the greatest benefit in PS-CF. Methods: MarketScan (2012–2018) was queried for AP hospitalizations and CFTR modulator use among patients with CF. Multivariable Poisson models that enabled crossover between CFTR modulator treatment groups were used to analyze the rate of AP hospitalizations on and off therapy. Pancreas insufficiency was defined by the use of pancreas enzyme replacement therapy. Results: A total of 10,417 patients with CF were identified, including 1,795 who received a CFTR modulator. AP was more common in PS-CF than PI-CF (2.9% vs 0.9%, P = 0.007). Overall, the observed rate ratio of AP during CFTR modulator use was 0.33 (95% confidence interval [CI] 0.10, 1.11, P = 0.07) for PS-CF and 0.38 (95% CI 0.16, 0.89, P = 0.03) for PI-CF, indicating a 67% and 62% relative reduction in AP hospitalizations, respectively. In a subset analysis of 1,795 patients who all had some CFTR modulator use, the rate ratio of AP during CFTR modulator use was 0.36 (95% CI 0.13, 1.01, P = 0.05) for PS-CF and 0.53 (95% CI 0.18, 1.58, P = 0.26) for PI-CF. DISCUSSION: CFTR modulator use is associated with a reduction in AP hospitalizations among patients with CF. These observational data support the prospective study of CFTR modulators to reduce AP hospitalizations among patients with CF.

18 November 2021 in Pancreatology
Verified
Journal Article
Closed access
FBFurqan A. Bhullar
Furqan A. Bhullar
MFMahya Faghih
Mahya Faghih
VAVenkata S. Akshintala
Venkata S. Akshintala
AAAhmed I. Ahmed
Ahmed I. Ahmed
KLKatie Lobner
Katie Lobner
Vikesh SinghVikesh Singh
Vikesh Singh